Table 2 Summary of treatment-related adverse events of all grades observed in ≥10% of patients. Data are presented as number (%)
Adverse events observed > 10% patients | All patients (n = 31) | |
|---|---|---|
Grade 1–2 | Grade ≥3 | |
Anemia | 17(54.8) | 5 (16.1) |
Fatigue | 15(48.4) | 4 (12.9) |
Nausea | 17 (54.8) | 0 (0) |
Lymphocytopenia | 2 (6.5) | 10 (32.3) |
Diarrhea | 10 (32.3) | 0 (0) |
Neutropenia | 5 (16.1) | 5 (16.1) |
Thrombocytopenia | 7 (22.6) | 2 (6.5) |
Decreased appetite | 9 (29.0) | 0 (0) |
Blood creatinine increased | 8 (25.8) | 0 (0) |
Vomiting | 6 (19.4) | 0 (0) |
Dysgueusia | 4 (12.9) | 1 (3.2) |
Vertigo | 4 (12.9) | 0 (0) |
Dyspepsia/Gastro-esophageal disease | 3 (9.7) | 1 (3.2) |
Dose reduction | 18 (58.0) | |
